174 related articles for article (PubMed ID: 34726773)
1. Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N; Zinzani PL; Morschhauser F; Dalle S; Maerevoet M; Michot JM; Ribrag V; Offner F; Beylot-Barry M; Moins-Teisserenc H; Zwaenepoel K; de Winne K; Battistella M; Hultberg A; Gandini D; Moshir M; Jacobs J; Delahaye T; Khan A; Zabrocki P; Silence K; van Rompaey L; Borg C; Motta G; Melle F; Calleri A; Pauwels P; de Haard H; Pileri S; Bagot M
Cancer; 2022 Mar; 128(5):1004-1014. PubMed ID: 34726773
[TBL] [Abstract][Full Text] [Related]
2. An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.
De Meulenaere A; Vermassen T; Creytens D; De Keukeleire S; Delahaye T; Deron P; Duprez F; Fung S; Pauwels P; Ferdinande L; Rottey S
Clin Transl Sci; 2021 Nov; 14(6):2300-2313. PubMed ID: 34405542
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Riether C; Pabst T; Höpner S; Bacher U; Hinterbrandner M; Banz Y; Müller R; Manz MG; Gharib WH; Francisco D; Bruggmann R; van Rompaey L; Moshir M; Delahaye T; Gandini D; Erzeel E; Hultberg A; Fung S; de Haard H; Leupin N; Ochsenbein AF
Nat Med; 2020 Sep; 26(9):1459-1467. PubMed ID: 32601337
[TBL] [Abstract][Full Text] [Related]
4. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
5. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
Wu CH; Wang L; Yang CY; Wen KW; Hinds B; Gill R; McCormick F; Moasser M; Pincus L; Ai WZ
Blood Adv; 2022 Apr; 6(7):2290-2302. PubMed ID: 34872108
[TBL] [Abstract][Full Text] [Related]
7. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
8. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Pabst T; Vey N; Adès L; Bacher U; Bargetzi M; Fung S; Gaidano G; Gandini D; Hultberg A; Johnson A; Ma X; Müller R; Nottage K; Papayannidis C; Recher C; Riether C; Shah P; Tryon J; Xiu L; Ochsenbein AF
Haematologica; 2023 Jul; 108(7):1793-1802. PubMed ID: 36779592
[TBL] [Abstract][Full Text] [Related]
9. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Aftimos P; Rolfo C; Rottey S; Offner F; Bron D; Maerevoet M; Soria JC; Moshir M; Dreier T; Van Rompaey L; Michot JM; Silence K; Hultberg A; Gandini D; de Haard H; Ribrag V; Peeters M; Thibault A; Leupin N; Awada A
Clin Cancer Res; 2017 Nov; 23(21):6411-6420. PubMed ID: 28765328
[No Abstract] [Full Text] [Related]
10. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
13. Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment.
Ikezoe T; Usuki K; Aida K; Hatayama T; Shirahase T; Yamauchi T
Cancer Sci; 2023 Mar; 114(3):1037-1044. PubMed ID: 36394119
[TBL] [Abstract][Full Text] [Related]
14. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
16. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
Mukai M; Mould D; Maeda H; Narushima K; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
19. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.
Li S; Chen D; Guo H; Liu D; Yang C; Zhang R; Wang T; Zhang F; Bai X; Yang Y; Sun N; Zhang W; Zhang L; Zhao G; Peng L; Tu X; Tian W
Front Oncol; 2023; 13():1240061. PubMed ID: 37849799
[TBL] [Abstract][Full Text] [Related]
20. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
